Medical Professionals Reference (MPR)Once-Monthly Weltruza Approved for Schizophrenia

📋 Regulatory Action / Label Change

The FDA approved Weltruza, the first once-monthly subcutaneous long-acting injectable formulation of olanzapine for adults with schizophrenia. Approval was supported by the randomized, double-blind, placebo-controlled SOLARIS trial and the established efficacy of oral olanzapine. Adults experiencing acute schizophrenia exacerbations received monthly injections of one of three Weltruza doses or placebo. All active-treatment groups demonstrated significant improvements in schizophrenia symptom severity at eight weeks, with sustained improvements observed through 48 weeks in the open-label extension period. The article reports regulatory approval supported by clinical trial evidence rather than comparative effectiveness against other long-acting antipsychotics.

Clinical Considerations

• The FDA approved Weltruza as the first once-monthly subcutaneous long-acting injectable olanzapine for adults with schizophrenia.
• The formulation is designed to provide steady olanzapine exposure with no loading dose, no oral supplementation, and no post-injection monitoring requirement.
• At week 8, PANSS total scores improved versus placebo across all dose groups, with mean differences of −9.75, −11.27, and −9.76 points for the 318 mg, 425 mg, and 531 mg regimens, respectively.
• Statistically significant improvements were also reported in CGI-S and Personal and Social Performance (PSP) scores.
• Patients entering the open-label phase demonstrated sustained improvements through 48 weeks of treatment.
• The reported safety profile was consistent with other olanzapine formulations, although the article does not provide detailed comparative safety data.

Practice Applications

• Consider long-acting injectable olanzapine as a newly available treatment option for adults with schizophrenia when medication adherence is a concern.
• Review differences between this formulation and existing long-acting antipsychotics, including administration requirements and monitoring considerations.
• Discuss long-acting treatment preferences with appropriate patients and caregivers as part of shared decision-making.
• Monitor effectiveness, tolerability, and functional outcomes after treatment initiation according to routine schizophrenia care standards.
• Interpret trial results within the context of placebo-controlled evidence; comparative effectiveness against other long-acting injectable antipsychotics remains uncertain.